Yahoo Finance Eve & Co. Announces Cannabis Supply Agreement With Adjupharm GmbH and Provides a Corporate Update
STRATHROY, Ontario, July 13, 2021 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (“Eve & Co”, “we”, “us” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF), is pleased to announce that its wholly-owned subsidiary, Natural MedCo Ltd. (“NMC”) has successfully entered into a Cannabis Supply Agreement (the “Agreement”) with Adjupharm GmbH (“AP”), an importer, exporter and distributor of para-pharmaceutical, medicinal and narcotics, headquartered in Bad Oldesloe, Germany.
Under the initial three-year agreement, AP is expected to order up to 660 kilograms of NMC’s dried and gamma-irradiated cannabis flowers. AP will distribute the products into the German market. AP is a leading certified medical cannabis distributor in the European Union. As a patient-first company and trusted partner of the global medical community, AP is focused on partnering with the best-in-class producers of the highest-quality medical cannabis strains to satisfy the requirements of their clients.
“We are very excited to have the opportunity to work with such a well-established and diverse pharmaceutical company as Adjupharm for distribution of our products and to support Adjupharm as one of the leading providers of medical cannabis in Germany,” commented Melinda Rombouts, President and Chief Executive Officer at Eve & Co.
The Company also announces that Ivan Ross Vrána has departed from his role as the Company’s Vice President, Governmental Relations and Business Development to pursue other interests. The Company’s Board of Directors would like to thank Mr. Vrána for his invaluable contributions to the Company since May 2019.
ABOUT EVE & CO
Eve & Co, through its wholly-owned subsidiary Natural MedCo Ltd., holds cultivation and processing licenses under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and extraction of cannabis oil and has received EU GMP certification. Natural MedCo Ltd. was Canada’s first female-founded licensed producer of medicinal marijuana and received its cultivation license from Health Canada in 2016. Eve & Co is led by a team of agricultural experts and has a licensed 1,000,000 sq. ft. greenhouse located in Strathroy, Ontario.
The Company’s website can be visited at www.evecannabis.ca
The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur, and include, but are not limited to, the production and sale of bath bombs by the Company, whether sales of bath bombs will occur, if any at all, or recur and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guaranteeing of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s management’s discussion and analysis dated May 31, 2021 (the “MD&A”) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. The Company cautions that the list of risks, uncertainties and other factors described in the MD&A is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
For further information, please contact: | |
Melinda Rombouts | |
Rory Taylor | |
